Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts
Qing Chang(Ontario Institute for Cancer Research), David W. Hedley(Ontario Institute for Cancer Research)
Cited by 34
Related Papers
Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial
|Clinical Cancer Research|2017|635
Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers
|British Journal of Cancer|2014|437
Germline <i>BRCA</i> Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma
|Journal of Clinical Oncology|2015|396
Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer
|British Journal of Cancer|2008|155
Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts
|British Journal of Cancer|2009|124